irinotecan has been researched along with titanium dioxide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Gong, S; Li, N; Pan, W; Tang, B; Wang, J; Yu, L | 1 |
| Ao, Y; Liu, Y; Tong, L; Yu, T; Zhang, G; Zhang, H | 1 |
2 other study(ies) available for irinotecan and titanium dioxide
| Article | Year |
|---|---|
A nuclear-targeted titanium dioxide radiosensitizer for cell cycle regulation and enhanced radiotherapy.
Topics: Cell Cycle; Cell Line, Tumor; Cell Nucleus; Humans; Irinotecan; Metal Nanoparticles; Microscopy, Electron, Transmission; Oligopeptides; Radiation-Sensitizing Agents; Radiotherapy; Reactive Oxygen Species; Titanium; Topoisomerase I Inhibitors; X-Rays | 2019 |
NIR triggered PLGA coated Au-TiO
Topics: Biocompatible Materials; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Delivery Systems; Humans; Irinotecan; Metal Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer; Thyroid Cancer, Papillary; Titanium; Topoisomerase I Inhibitors; Treatment Outcome | 2020 |